Ovarian Cancer

Use of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Has Doubled

By

Leah Lawrence

Publish Date October 2, 2020

Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.

Hyperthermic Intraperitoneal Chemotherapy May Improve Outcomes in Epithelial Ovarian Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date October 1, 2020

Hyperthermic intraperitoneal chemotherapy added to cytoreductive surgery improved outcomes compared with surgery alone in a cohort study.

Frailty Linked to Poor Postsurgical Outcomes in Patients With Ovarian Cancer

By

Vicki Moore, PhD

Publish Date September 22, 2020

In a review of data from the Nationwide Readmissions Database, researchers found that women with ovarian cancer classified as frail were at higher risk for need of intensive care, nonroutine discharge, and readmissions after surgery.

American Cancer Society Updates Cervical Cancer Screening Guidelines

By

Victoria Forster, PhD

Publish Date September 16, 2020

New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.

PARP Inhibitors Deemed Too Costly For Across-the-Board Frontline Maintenance in Ovarian Cancer

By

Leah Lawrence

Publish Date September 16, 2020

Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.

Ovarian Cancer Clinical Trials

Clinical Trial: Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Clinical Trial: Prophylactic Salpingectomy With Delayed Oophorectomy

Clinical Trial: Interactive Educational Website for Women With Ovarian Cancer & Caregivers

Clinical Trial: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Clinical Trial: AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer